Icon eyeing China
Icon is looking to expand its bioanalytical capacity in Asia, notably in China, and bolster its genomics, proteomics and cell-based assay capabilities, according to a VP who discussed diversification of the business.
Archives for November 24, 2009
Millipore buys Indian JV
Millipore has acquired the remaining 60 per cent of its Indian joint venture (JV) to drive growth in the country which it views, along with the other BRICS nations, as a critical part of its strategy.
14 C "synth to clinic" simplifies development process, says Quotient CEO
UK contract services firm Quotient Bioresearch says its "Synthesis-to-clinic" service for 14 C labelled compounds can simplify early drug development.
Sistemic setting up in US
Sistemic is targeting the US by setting up an office in Boston, Mass, from which it will promote its services that use miRNA to identify and understand a compound’s activity in a simpler way than genomics or proteomics.
Servier’s Irish R&D and manufacturing plant opens
French drugmaker Servier has opened a new €47m manufacturing and R&D facility in Ireland.
Merck KGaA plans €150m clinical R&D centre in China
Merck KGaA says China’s growing drug market is the key driver for the new €150m ($224m) clinical R&D hub it plans to set up in Beijing.
GSK puts hold on Canadian batch of H1N1 vacc
GSK has asked several Canadian provinces to stop using one batch of its H1N1 vaccine after a higher than expected number of allergic reactions.